Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.82 |
| ▸ | EGFR | P00533 | 13/20 | 0.70 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | FES | P07332 | 1/20 | 0.62 |
| ▸ | FER | P16591 | 1/20 | 0.62 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.62 |
| ▸ | TEC | P42680 | 1/20 | 0.62 |
| ▸ | CLK1 | P49759 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.62 |
| ▸ | ULK1 | O75385 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752965 | 0.90 | ALK (1.00) | ALKEGFRULK1 | |
| SCHEMBL17531020 | 0.87 | ALK (0.83) | ALKEGFRGAKFESFER | |
| SCHEMBL30221574 | 0.85 | ALK (0.82) | ALKEGFRGAKFESFER | |
| SCHEMBL28584782 | 0.84 | EGFR (0.79) | ALKEGFRGAKFESFER | |
| SCHEMBL16752944 | 0.83 | ALK (1.00) | ALK | |
| SCHEMBL16752967 | 0.83 | ALK (1.00) | ALK | |
| SCHEMBL21846968 | 0.82 | EGFR (1.00) | ALKEGFR | |
| SCHEMBL29832366 | 0.82 | EGFR (1.00) | ALKEGFR | |
| SCHEMBL26612049 | 0.80 | ALK (0.75) | ALKEGFRPTK2ULK1 | |
| SCHEMBL26161575 | 0.80 | ALK (0.85) | ALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029002-A2 | GROWTH FACTOR RECEPTOR INHIBITORS | CLOVIS ONCOLOGY, INC. (US) | 2016-02-25 | — | — | WO | disclosed |